Tenapanor治疗维持性血液透析患者高磷血症的疗效与安全性:随机3期试验
这项3期随机双盲试验纳入219例接受维持性血液透析的高磷血症患者,先接受8周Tenapanor(3、10或30mg每日两次)治疗,随后1:1再随机接受原剂量或安慰剂4周撤药期。结果显示Tenapanor显著降低血清磷,撤药期安慰剂组平均升高0.85mg/dl而Tenapanor组仅升高0.02mg/dl,不良事件主要为软便和排便次数增加。
要点
- Tenapanor 3、10、30mg组8周内血清磷分别平均降低1.00、1.02、1.19mg/dl
- 撤药期安慰剂组血清磷平均升高0.85mg/dl,Tenapanor组仅升高0.02mg/dl
- 不良事件主要为软便和排便次数增加,与其增加粪便钠水含量的机制一致
核心结论
- Tenapanor可显著降低维持性血液透析高磷血症患者的血清磷水平。
- 其不良反应主要限于机制相关的软便和排便次数增加。
研究设计与样本
- 3期随机双盲试验,219例维持性血液透析高磷血症患者随机接受Tenapanor 3、10或30mg每日两次治疗8周。
- 随后1:1再随机接受原剂量或安慰剂4周撤药期,152例完成两阶段。
主要发现
- 8周治疗期内3、10、30mg组血清磷分别平均降低1.00、1.02、1.19mg/dl。
- 撤药期安慰剂组血清磷平均升高0.85mg/dl,Tenapanor合并组仅升高0.02mg/dl。
- 不良事件主要为软便和排便次数轻度增加。
临床怎么用
- 对于维持性血液透析高磷血症患者,Tenapanor可作为降低血清磷的治疗选择。
- 用药期间需关注软便和排便次数增加等机制相关不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend reducing elevated serum phosphate in patients with CKD. Tenapanor, a minimally absorbed inhibitor of gastrointestinal sodium/hydrogen exchanger 3 (NHE3), reduces paracellular phosphate transport. METHODS: In this phase 3 randomized, double-blind trial, we randomly assigned patients with hyperphosphatemia receiving maintenance hemodialysis to receive twice-daily oral tenapanor (3, 10, or 30 mg [the latter down-titrated, if needed]) for 8 weeks. Patients were then rerandomized 1:1 to receive either their previously assigned dose or placebo for a 4-week 'withdrawal' period. We measured serum phosphate levels over the course of the trial. The primary end point was mean change in serum phosphate over the 4-week withdrawal period for the tenapanor group (using pooled data) versus the placebo group. RESULTS: Of 219 patients randomized, 152 completed both study phases. During the initial 8-week treatment period, all three treatment groups experienced significant decreases in mean serum phosphate (reductions of 1.00, 1.02, and 1.19 mg/dl, corresponding to the 3, 10, and 30 mg [down-titrated] dose groups, respectively). Tenapanor also showed a significant benefit over placebo during the withdrawal period, with a mean increase of 0.85 mg/dl in the placebo group versus a mean increase of 0.02 mg/dl in the pooled tenapanor group. Adverse events were largely limited to softened stool and a modest increase in bowel movement frequency, resulting from increased stool sodium and water content, stemming from tenapanor's mechanism of action. CONCLUSIONS: Tenapanor significantly reduced elevated serum phosphate in patients with hyperphosphatemia receiving maintenance hemodialysis. Adverse effects were limited to those induced by its known mechanism of action, which increases stool sodium and water content.
引用
- Block GA, Rosenbaum DP, Yan A, et al. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J Am Soc Nephrol. 2019. PMID: 30846557. doi:10.1681/ASN.2018080832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。